Article Details
Retrieved on: 2021-05-10 13:07:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The capital will accelerate the development of Therini's lead program – a monoclonal antibody against fibrin – towards the clinic for patients with ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here